Sino Biopharmaceutical

LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.

HanchorBio is a biotechnology research firm focused on developing innovative drugs for cancer treatment. The company specializes in drug discovery based on tumor immunology, with the goal of enhancing the quality of life for cancer patients. Through its research and development efforts, HanchorBio aims to revolutionize existing treatment paradigms and provide effective therapeutic options for those affected by cancer.

Generon (Shanghai) Corporation Ltd. is a biotechnology company based in Shanghai, China, specializing in the discovery, development, and production of biomedicines. The company focuses on creating therapeutic recombinant proteins aimed at treating cancer and autoimmune as well as inflammatory diseases. Generon operates a research and development center located in Zhang Jiang High-Tech Park and a cGMP drug manufacturing facility in Beijing. The company employs advanced technology platforms to bring innovative biologic therapeutics to market, addressing unmet medical needs on a global scale. Generon adheres to international quality standards and regulatory requirements set forth by the CFDA, FDA, and EMA, emphasizing innovation and quality throughout its drug discovery, development, and manufacturing processes.

Medlinker operates as a social networking platform specifically designed for certified doctors, enabling them to connect with peers and access high-quality medical information. The platform facilitates knowledge sharing among healthcare professionals, allowing users to exchange experiences and insights. It offers various features, including medical quizzes, case mapping, and anonymous social circles, aimed at enhancing collaboration within the medical community. Additionally, Medlinker connects verified doctors with healthcare institutions, pharmaceutical companies, patients, and insurance firms, streamlining the process for patients to book medical appointments and submit inquiries to the medical community. Through these functionalities, Medlinker aims to improve the efficiency of healthcare interactions and support physicians in their professional development.

Treadwell Therapeutics Inc. is a clinical-stage oncology company focused on developing innovative therapeutics to meet unmet medical needs in cancer treatment. Founded in 2019 in New York, the company has a robust pipeline that includes several promising candidates, such as CFI-400945, a first-in-class PLK4 kinase inhibitor, and CFI-402257, a best-in-class TTK inhibitor. Additionally, Treadwell is advancing CFI-402411, an oral immunomodulatory kinase inhibitor targeting HPK1. The company also boasts a diverse pre-clinical pipeline featuring multiple biologic and next-generation TCR-based autologous cell therapy programs. With a commitment to exploiting cancer cell vulnerabilities, Treadwell Therapeutics aims to enhance recovery for patients through its innovative drug development efforts.

XtalPi Inc. is a pharmaceutical technology company that focuses on digital drug development solutions, leveraging quantum mechanics and artificial intelligence to enhance the efficiency of drug research and development. Founded in 2014 by a group of quantum physicists at MIT, the company has developed its Intelligent Digital Drug Discovery and Development (ID4) platform, which integrates advanced cloud computing algorithms to aid pharmaceutical firms in critical stages of drug R&D. XtalPi offers various tools, including XtalForc for visual force field calculations, XtalVision for crystal structure predictions, and Renova for platform support of its AI research initiatives. Its comprehensive services encompass crystal structure determination, solid-state testing, small molecule drug design, and collaborations in antibody and peptide research. Based in Cambridge, Massachusetts, with additional offices in China, XtalPi has established strategic partnerships with leading international pharmaceutical companies, demonstrating the broad applicability and recognition of its innovative technologies across the pharmaceutical value chain.

Softhale is a medical device company specializing in the development of Soft Mist Inhalation (SMI) devices designed for the effective delivery of pharmaceutical drugs to the lungs. The company's innovative devices utilize a proprietary set of technical configurations to spray a propellant-free liquid formulation efficiently. This design allows the medication to navigate the natural curve of the throat, giving patients the opportunity to inhale the treatment deeply into their lungs. By enhancing the delivery of inhalable therapeutics, Softhale aims to improve respiratory treatments and provide relief for individuals suffering from chronic respiratory conditions.

Sinovac Life Sciences is a research-based company that conducts human vaccine research, development, manufacturing, and sales.

Akeso Biopharma, Inc. is a contract research organization based in Zhongshan, China, specializing in the discovery and development of antibody and protein drugs. Established in 2012, the company offers a range of integrated services to both domestic and international pharmaceutical firms, including protein expression and purification, antibody generation, assay development, humanization, and affinity maturation. Akeso has developed a comprehensive biopharmaceutical research and development platform, focusing on therapeutic areas such as cancer, autoimmune diseases, inflammation, and cardiovascular diseases. With a robust pipeline of over 30 drug candidates, 17 of which are in clinical stages, Akeso is recognized for its innovative approaches, including the development of first-in-class bi-specific antibody drugs. The company collaborates with various pharmaceutical enterprises to advance the joint development of new drugs, positioning itself as a leader in the biopharmaceutical industry.

LifeBond Ltd. is a developer and manufacturer of absorbable bio-surgical medical devices focused on tissue repair, aiming to enhance patient recovery and support the body's natural healing process. Founded in 2006 and based in Caesarea, Israel, the company offers a range of products, including the LifeSeal Surgical Sealant, which provides reinforcement to minimize post-operative complications such as staple-line leakage in various surgical procedures. Another key product, LifeMesh Self-Fixating Mesh, is designed for secure fixation during hernia repair, addressing post-surgical complications effectively. In addition to these products, LifeBond is engaged in the development of tissue adhesives and absorbable hemostats. Their innovative devices are designed to meet a variety of surgical needs and are available in markets including China, the United States, and Europe, although many products remain investigational and have not yet received market approval.